Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291134 · ClinicalTrials.gov registry record
PureGen: Radiographic Analysis of Fusion for ACDF
A clinical trial, sponsored by Alphatec Spine.
- Terminated
- Registry status
- 30
- Enrollment target
NCT01291134: Clinical Trial study, sponsored by Alphatec Spine.
NCT01291134 is a clinical trial that was terminated before completion, run by Alphatec Spine. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01291134 was terminated before completion, sponsored by Alphatec Spine.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).
Primary Outcome
Proportion of subjects with fusion at the 12-month visit
Interventions
- BIOLOGICAL PureGen Osteoprogenitor Cell Allograft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-08 |
Why NCT01291134 stopped before completion
NCT01291134 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PureGen Osteoprogenitor Cell Allograft is the first listed.
NCT01291134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01291134 about?
NCT01291134 is a clinical study titled "PureGen: Radiographic Analysis of Fusion for ACDF". The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).
What is the current status of trial NCT01291134?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2011-02. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01291134?
The interventions under investigation include: PureGen Osteoprogenitor Cell Allograft (BIOLOGICAL).
Who is sponsoring clinical trial NCT01291134?
This trial is sponsored by Alphatec Spine, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia